Tianmu Pharmaceutical announced that Huilong Huaze, the controlling shareholder of the company, holds 29.99% of the company's shares and plans to transfer 24.355,800 shares through a public collection agreement, accounting for 20% of the total share capital. After the transfer was completed, Huilong Huaze's shareholding fell to 9.99%. This matter may cause changes in the controlling shareholder and actual controller of the company. The transfer still requires approval from the state-owned assets department, and the transferee is uncertain. The final transfer price will be determined in accordance with relevant regulations.

Tianmu Pharmaceutical announced that Huilong Huaze, the controlling shareholder of the company, holds 29.99% of the company's shares and plans to transfer 24.355,800 shares through a public collection agreement, accounting for 20% of the total share capital. After the transfer was completed, Huilong Huaze's shareholding fell to 9.99%. This matter may cause changes in the controlling shareholder and actual controller of the company. The transfer still requires approval from the state-owned assets department, and the transferee is uncertain. The final transfer price will be determined in accordance with relevant regulations.